Drugs for Stargardt Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 18)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Metformin |
Approved |
Phase 1, Phase 2 |
|
1115-70-4, 657-24-9 |
4091 |
Synonyms:
[<sup>14</sup>C]-metformin
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
1-CARBAMIMIDAMIDO-N,N-DIMETHYLMETHANIMIDAMIDE
Apo-Metformin
BOLAMYN SR
Diabefagos
Diabex
Diaformin
DIAGEMET XL
Dianben
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
DMBG
Fortamet
Gen-Metformin
GLUCAMET 500
GLUCAMET 850
GLUCIENT SR
Glucophage
GLUCOPHAGE SR
GLUCOPHAGE XR
Glumetza
Glycon
GLYFORMIN
HCL, Metformin
Hydrochloride, metformin
JANUMET
LA 6023
LA-6023
|
LEDERMETIN
Meguan
METABET SR
Metformin
Metformin HCL
Metformin hydrochloride
Metformina
Metformine
Metforminum
Metiguanide
METSOL
MILFORM
Mylan-Metformin
N(1),N(1)-Dimethylbiguanide
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylguanylguanidine
N,N-Dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
Novo-Metformin
NSC-91485
Nu-Metformin
Obimet
ORABET
PMS-Metformin
Ran-Metformin
Ratio-Metformin
Riomet
Sandoz Metformin
SUKKARTO SR
Teva-Metformin
XLA399
|
|
2 |
|
Acetic acid |
Approved |
Phase 2 |
|
64-19-7 |
176 |
Synonyms:
Acetasol
Acetate
acetate|ethanoic acid
Acetic acid
Acetic acid glacial
Acetic acid, glacial
Aceticum acidum
Acid glacial, acetic
Acid, acetic
Acid, glacial acetic
Acide acetique
acide acétique
ácido acético
AcOH
CH3CO2H
CH3-COOH
e 260
e260
e-260
Essigsaeure
|
Essigsäure
Ethanoat
Ethanoate
Ethanoic acid
Ethoate
Ethoic acid
Ethylate
Ethylic acid
Glacial acetate
Glacial acetic acid
Glacial, acetic acid
HOAc
INS no. 260
Kyselina octova
MeCO2h
MeCOOH
Methanecarboxylate
Methanecarboxylic acid
Vinegar
Vinegar acid
|
|
3 |
|
Vitamin A |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
22737-96-8, 68-26-8 |
5280382 445354 |
Synonyms:
(2E,4E,6E,8E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYLCYCLOHEX-1-EN-1-YL)NONA-2,4,6,8-TETRAEN-1-OL
(ALL-E)-3,7-DIMETHYL-9-(2,6,6-TRIMETHYL-1-CYCLOHEXEN-1-YL)-2,4,6,8-NONATETRAEN-1-OL
11-CIS-RETINOL
11-cis-Vitamin a alcohol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-e)-isomer
all trans Retinol
all-trans-Retinol
ALL-TRANS-RETINYL ALCOHOL
ALL-TRANS-VITAMIN A ALCOHOL
ALPHALIN
Aquasol a
AROVIT
BETA-RETINOL
B-RETINOL
CHOCOLA A
cis-11-Retinol
|
NEPALM
NSC-122759
OLEOVITAMIN A
Retinol
RETINOL (VIT A)
RETINOL ACETATE
RETINOL PALMITATE
Retinolum
RO-A-VIT
TRANS-RETINOL
Vitamin a
VITAMIN A 1
VITAMIN A OIL
VITAMIN A SOLUBILIZED
Vitamin a1
|
|
4 |
|
Zuretinol acetate |
Investigational |
Phase 2 |
|
127-47-9, 29584-22-3 |
10245972 |
Synonyms:
(2E,4E,6Z)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-yl acetic acid
13-cis-Retinyl acetate
9-cis-Retinyl acetate
Acetateall-trans-retinol
Acetic acid, retinyl ester
all-trans-Retinol acetate
all-trans-Retinyl acetate
all-trans-Retinylacetate
all-trans-Vitamin a acetate
Crystalets
Dagravit a forte
Davitan a 650
Dif vitamin a masivo
Myvak
Myvax
O(15)-Acetylretinol
O~15~-acetylretinol
O~15~-acetyl-retinol
RetiNit
Retinol acetate
|
Retinol acetate (JP15)
RETINOL acetATE (see retinoidprojects 1 and 3)
Retinol acetate, (9,13-cis)-isomer
Retinol acetic acid
Retinol, acetate
Retinol, acetate, all-trans- (8ci)
Retinol, acetate, labeled with tritium
Retinyl acetate
trans-Retinyl acetate
trans-Vitamin a acetate
Vitamin a acetate
Vitamin a acetate (tritiated)
Vitamin a alcohol acetate
Vitamin a dispersa
Vitamin a ester
Vitamin a, acetate
Vitamin a1 acetate
Vitamin-a-saar
Zuretinol acetate
Zuretinol acetic acid
|
|
5 |
|
Complement System Proteins |
|
Phase 2 |
|
|
|
6 |
|
Hypoglycemic Agents |
|
Phase 1, Phase 2 |
|
|
|
7 |
|
Vitamins |
|
Phase 2 |
|
|
|
8 |
|
Adjuvants, Immunologic |
|
Phase 2 |
|
|
|
9 |
|
Trace Elements |
|
Phase 2 |
|
|
|
10 |
|
Micronutrients |
|
Phase 2 |
|
|
|
11 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
12 |
|
Retinol palmitate |
|
Phase 2 |
|
|
|
13 |
|
Protective Agents |
|
Phase 2 |
|
|
|
14 |
|
Pharmaceutical Solutions |
|
Phase 1, Phase 2 |
|
|
|
15 |
|
Fomepizole |
Approved, Vet_approved |
Phase 1 |
|
7554-65-6 |
3406 |
Synonyms:
4 Methylpyrazole
4 Methylpyrazole monohydrochloride
4-Methylpyrazol
4-Methylpyrazole
4-Methylpyrazole monohydrochloride
|
4-MP
Antizol
Fomepizol
FOMEPIZOLE
Fomepizolum
|
|
16 |
|
Omega 3 Fatty Acid |
|
Phase 1 |
|
|
|
17 |
|
Antidotes |
|
Phase 1 |
|
|
|
18 |
|
Sunflower |
|
|
|
|
|
Interventional clinical trials:
(show all 39)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride With Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease |
Completed |
NCT03772665 |
Phase 3 |
Emixustat;Placebo |
2 |
Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects |
Recruiting |
NCT05244304 |
Phase 3 |
Tinlarebant;Placebo |
3 |
Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases |
Unknown status |
NCT02749734 |
Phase 1, Phase 2 |
|
4 |
A Novel Therapeutic Strategy Targeting Photoreceptor Oxidative Damage in ABCR-related Retinal Degenerations |
Unknown status |
NCT01278277 |
Phase 1, Phase 2 |
|
5 |
A Phase 2a Study of the Safety, Pharmacokinetics and Pharmacodynamics of STG-001 in Subjects With Stargardt Disease (STGD1) Caused by Autosomal Recessive Mutation in ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene |
Completed |
NCT04489511 |
Phase 2 |
STG-001 |
6 |
A Phase 2a Multicenter, Randomized, Masked Study Evaluating the Pharmacodynamics of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease |
Completed |
NCT03033108 |
Phase 2 |
Emixustat |
7 |
A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) |
Completed |
NCT01469832 |
Phase 1, Phase 2 |
|
8 |
A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) |
Completed |
NCT01345006 |
Phase 1, Phase 2 |
|
9 |
Stem Cell Derived Retinal Pigmented Epithelium Implantation in Patients With Outer Retinal Degenerations: Phase I/II Clinical Trial |
Completed |
NCT02903576 |
Phase 1, Phase 2 |
|
10 |
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease |
Recruiting |
NCT02402660 |
Phase 2 |
ALK-001;Placebo |
11 |
A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimuraâ„¢ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease |
Recruiting |
NCT03364153 |
Phase 2 |
Zimura |
12 |
Oral Metformin for Treatment of ABCA4 Retinopathy |
Recruiting |
NCT04545736 |
Phase 1, Phase 2 |
Metformin hydrochloride |
13 |
Phase 1/2, Open-Label, Dose-Finding Followed by 2-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease |
Active, not recruiting |
NCT05266014 |
Phase 1, Phase 2 |
tinlarebant |
14 |
A Phase 2a, Open Label Multicenter Clinical Trial to Evaluate the Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease |
Active, not recruiting |
NCT05417126 |
Phase 2 |
|
15 |
An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration |
Active, not recruiting |
NCT01736592 |
Phase 1, Phase 2 |
Long term follow up in all patients who received SAR422459 in previous study TDU13583 |
16 |
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease |
Enrolling by invitation |
NCT04239625 |
Phase 2 |
ALK-001 |
17 |
A Phase I/IIA Dose Escalation Safety Study of Subretinally Injected SAR422459, Administered to Patients With Stargardt's Macular Degeneration |
Terminated |
NCT01367444 |
Phase 1, Phase 2 |
SAR422459 |
18 |
Stem Cells Therapy in Degenerative Diseases of the Retina |
Unknown status |
NCT03772938 |
Phase 1 |
|
19 |
A Phase I, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy(SMD) |
Unknown status |
NCT01625559 |
Phase 1 |
|
20 |
A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy Volunteers |
Completed |
NCT02230228 |
Phase 1 |
ALK-001 (No generic name) |
21 |
Investigation of the Effect of Dietary Docosahexaenoic Acid (DHA) Supplementation on Macular Function in Subjects With Autosomal Dominant Stargardt-Like and Autosomal Recessive Stargardt Macular Dystrophy |
Completed |
NCT00060749 |
Phase 1 |
Docosahexaenoic Acid (DHA) Dietary Supplement |
22 |
Clinical Interventions Against Stargardt Macular Dystrophy: Phase 1 Pilot Study of 4-MP as an Inhibitor of Dark Adaptation |
Completed |
NCT00346853 |
Phase 1 |
4-Methylpyrazole |
23 |
Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision |
Unknown status |
NCT04281732 |
|
|
24 |
Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease |
Completed |
NCT01977846 |
|
|
25 |
The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4 (STGD4): A Prospective Longitudinal Observational Study of Stargardt Disease Type 4, a PROM1- Related Macular Dystrophy |
Completed |
NCT02410122 |
|
|
26 |
Prospective, Randomised, Double-blind Study to Assess the Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (Macular Degeneration Omega-3 Study - MADEOS |
Completed |
NCT03297515 |
|
|
27 |
¿Es Util la Acupuntura en la Degeneracion Macular? Prospective Study of Efficacy of Acupuncture in Macular Diseases |
Completed |
NCT02255981 |
|
|
28 |
New Methods of Dynamic Pupillometrics in Subjects With Visual and Color Vision Pathologies for the Detection, Functional Diagnosis and Follow-up of These Pathologies |
Completed |
NCT04909398 |
|
|
29 |
Clinical Interventions Against Stargardt Macular Dystrophy: DHA Supplementation in Patients With STGD3 |
Completed |
NCT00420602 |
|
|
30 |
Long Term Follow Up to a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) |
Completed |
NCT02445612 |
|
|
31 |
Follow-up to 5 Years of a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD) |
Completed |
NCT02941991 |
|
|
32 |
An Observational, Multi-Center Phase 1 Study of the Safety and Effectiveness of Frequency Specific Microcurrent Stimulation as an Alternative Treatment for Retinal Diseases |
Completed |
NCT01790958 |
|
|
33 |
Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II |
Recruiting |
NCT03011541 |
|
|
34 |
Structural and Functional Characterization of Rare Ocular Diseases |
Recruiting |
NCT05258032 |
|
|
35 |
Foundation Fighting Blindness My Retina Tracker Registry |
Recruiting |
NCT02435940 |
|
|
36 |
Rod and Cone Mediated Function in Retinal Disease |
Recruiting |
NCT02617966 |
|
|
37 |
Natural History of ABCA4-Related Retinopathies |
Active, not recruiting |
NCT01736293 |
|
|
38 |
Novel Quantification Methods for Fundus Flavoprotein Fluorescence and Lipofuscin Fluorescence to Detect Progression in Stargardt Disease |
Terminated |
NCT01676766 |
|
|
39 |
Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy |
Terminated |
NCT02875704 |
|
|
Cell-based therapeutics:
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Stargardt Disease:
Embryonic/Adult Cultured Cells Related to Stargardt Disease:
|